DEC 09, 2015 10:43 AM PST

Brain-based Biomarkers Better at Classifying Psychotic Disorders

WRITTEN BY: Xuan Pham
In a move towards objectivity and higher precision, researchers at the University of Georgia have identified a number of brain-based biomarkers that can be used to improve diagnosis of psychiatric conditions.   
 
Creating Neurobiologically Distinct Psychosis Biotypes
 
To diagnose infections, doctors run blood tests. To diagnose brain aneurysms, doctors do comprehensive brain scans. But to diagnose a psychiatric condition, doctors ask how you’re feeling. Progress of medical technologies has made it possible to scan, X-ray, sequence, probe patients in countless ways to get at accurate diagnoses. However, no objective tests exist for diagnosing mental illness.  
 
Instead of quantitative tests, diagnosis of psychiatric conditions is heavily dependent on observable symptoms. Clinicians rely on the Diagnostic and Statistical Manual of Mental Disorders (DSM) to subjectively categorize patients’ symptoms into certain disorders. This system of classifying mental illness has been criticized for being inherently incomplete and often biased. Incidentally, the DSM text is over 60 years old and has had a history of revisions.
 
"Psychiatry still relies on symptoms as the basis of a diagnosis," said the study's lead author Brett Clementz. "It would be like using the presence of fever to diagnose a specific infection. We need some means to help us more accurately differentiate mental disorders."
 
Inspired by objectivity of molecular diagnostic tools, the research team set out to identify disease types based on quantitative neurobiological measures. The large biomarker panel consisted of measures for many different brain functions, including those specific to cognition, visual, auditory, and sensory deficits. They also obtained data on social functioning, structural magnetic resonance imaging, family biomarkers and clinical information.
 
To see if the biomarker panels could delineate different psychiatric conditions, the researchers tested 711 patients with generalized psychosis, which is a defining characteristic of Schizophrenia, Schizoaffective Disorder, and Psychotic Bipolar Disorder. They then compared the data from patients with psychosis to data from over 1,000 first-degree relatives and healthy patients.
 
From their data analysis, the team identified 3 distinct “biotypes,” meaning 3 subgroups with different biomarker characteristics. Here are the 3 biotypes as summarized by the study results:

Biotype-1 cases were fewest in number, had low grey matter volume, significant neurobiological impairment, high numbers of clinically affected relatives, and poor psychosocial functioning.
 
Biotype-2 cases had high neural reactivity, modestly small grey matter volumes, and more modest but still significant cognitive impairment.
 
Biotype-3 cases were most numerous, had nearly normal cognition and neural reactivity, lowest numbers of clinically affected relatives, and the best psychosocial functioning.

The researchers reported their method of biotype classification was superior to the traditional DSM standards. "We were better able to predict who had family histories of psychoses, structural brain abnormalities and measures of social functioning when compared with DSM standards," Clementz said.
 
The results of this study challenge what used to be considered the gold standard of mental diagnosis. However, these biotype measures won’t be replacing the DSM soon, as more work needs to be done to evaluate its reliability across broader conditions. "We're a long way from identifying specific disease mechanisms, but we're a step closer than we were when we focused on clinical symptoms alone," said Clementz.
 
Watch the video to learn how clinical professionals react to the most recent update of the DSM.

Sources: American Journal of Psychiatry, Eurekalert
 
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 13, 2021
Cardiology
Can a Ketosis Metabolite Act as a Biomarker for Cardiovascular Diseases?
APR 13, 2021
Can a Ketosis Metabolite Act as a Biomarker for Cardiovascular Diseases?
Quick and reliable diagnostics are the key to controlling many diseases, including cardiovascular disease. Biomarkers ar ...
APR 20, 2021
Cardiology
Does Impaired Glucose Tolerance Increase Heart Damage After a Stroke?
APR 20, 2021
Does Impaired Glucose Tolerance Increase Heart Damage After a Stroke?
Diabetes is a looming threat to the world’s healthcare systems. Diagnoses of its precursors, impaired glucose tole ...
MAY 18, 2021
Genetics & Genomics
Library Prep Methods for SARS-CoV-2 Sequencing: a Summary
MAY 18, 2021
Library Prep Methods for SARS-CoV-2 Sequencing: a Summary
As the SARS-CoV-2 virus continues to mutate, rapid sequencing of COVID-19-positive samples is more critical than ever. N ...
MAY 26, 2021
Genetics & Genomics
Connecting Bacterial Genes to Human Disease
MAY 26, 2021
Connecting Bacterial Genes to Human Disease
This kind of research gets us closer to using fecal samples to get a snapshot of the microbiome, and make disease risk p ...
MAY 31, 2021
Clinical & Molecular DX
Researchers Create the First Saliva Wiki
MAY 31, 2021
Researchers Create the First Saliva Wiki
A new digital platform, developed by researchers at the University at Buffalo, is answering the question: what’s o ...
JUL 29, 2021
Clinical & Molecular DX
Sewage Sleuths: Tracking COVID Variants in Wastewater
JUL 29, 2021
Sewage Sleuths: Tracking COVID Variants in Wastewater
Since the dawn of the pandemic, one of the biggest challenges has been monitoring the crowned enemy as it spread through ...
Loading Comments...